mitoxantrone has been researched along with B-Cell Chronic Lymphocytic Leukemia in 61 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to determine the effectiveness and toxicity of cladribine (2-CdA) used alone or in combination with prednisone (P) or cyclophosphamide and mitoxantrone in re-treatment of patients with progressive B-cell chronic lymphocytic leukemia (B-CLL)." | 7.71 | Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. ( Boński, JZ; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, J; Hellmann, A; Kasznicki, M; Konopka, L; Robak, T; Wołowiec, D, 2002) |
| " These results support that fludarabine in combination with cyclophosphamide and/or mitoxantrone can be highly effective in the treatment of B-CLL." | 5.30 | In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. ( Bellosillo, B; Colomer, D; Gil, J; Montserrat, E; Pons, G; Villamor, N, 1999) |
| "The objective of the current study was to assess the efficacy of combination therapy with fludarabine and mitoxantrone in patients with B-cell chronic lymphocytic leukemia (CLL)." | 5.11 | Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. ( Andreeff, M; Beran, M; Ferrajoli, A; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Tsimberidou, AM; Wierda, WG, 2004) |
| "Prior studies of the combination of fludarabine, mitoxantrone and dexamethasone have yielded high response rates but are associated with a significant risk of opportunistic infections, predominantly Pneumocystis Carinii pneumonia (PCP) requiring routine prophylaxis." | 5.09 | Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. ( Fox, RM; Grigg, AP; Seymour, JF; Szer, J, 2001) |
| "The purpose of the study was to determine some apoptotic events in mononuclear cells obtained from peripheral blood of patients with B-cell chronic lymphocytic leukemia (B-CLL) during and after therapy with 2-chlorodeoxyadenosine (2-CdA; C), and the combination of 2-CdA with cyclophosphamide (CC), or 2-CdA with mitoxantrone and cyclophosphamide (CMC)." | 3.72 | 2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo. ( Błoński, JZ; Hanausek, M; Kiliańska, ZM; Robak, T; Rogalińska, M; Walaszek, Z, 2004) |
| "The role of Bax and Bak, 2 proapoptotic proteins of the Bcl-2 family, was analyzed in primary B-cell chronic lymphocytic leukemia (CLL) cells following in vitro treatment with fludarabine, dexamethasone, or the combination of fludarabine with cyclophosphamide and mitoxantrone (FCM)." | 3.71 | Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. ( Bellosillo, B; Bosch, F; Campo, E; Colomer, D; López-Guillermo, A; Marcé, S; Montserrat, E; Villamor, N, 2002) |
| "The aim of the study was to determine the effectiveness and toxicity of cladribine (2-CdA) used alone or in combination with prednisone (P) or cyclophosphamide and mitoxantrone in re-treatment of patients with progressive B-cell chronic lymphocytic leukemia (B-CLL)." | 3.71 | Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. ( Boński, JZ; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, J; Hellmann, A; Kasznicki, M; Konopka, L; Robak, T; Wołowiec, D, 2002) |
| "In addition, minimal residual disease (MRD) in the marrow was studied 2 months after therapy, with MRD negativity defined as <0·01% CLL cells." | 2.76 | A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. ( Booth, GA; Brown, J; Cocks, K; Cohen, DR; Dearden, C; Ezekwisili, R; Fegan, C; Hillmen, P; Kennedy, DB; Mercieca, J; Milligan, DW; Pettitt, A; Pocock, C; Radford, J; Rawstron, AC; Sayala, HA; Smith, AF; Varghese, AM, 2011) |
| "Of 79 evaluable patients, 58 (73%) had follicular lymphoma, 13 (16%) mantle cell lymphoma and 8 (10%) lymphoplasmacytic lymphoma." | 2.73 | Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group. ( Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M, 2007) |
| "The clinical significance of eradicating minimal residual disease (MRD) was also analyzed." | 2.73 | Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. ( Abella, E; Altés, A; Asensi, A; Aymerich, M; Bertazzoni, P; Bosch, F; Briones, J; Escoda, L; Ferrer, A; Font, L; Gardella, S; Giné, E; González, M; González-Barca, E; Montserrat, E; Muntañola, A; Pérez-Ceballos, E; Rozman, M; Sayas, MJ; Villamor, N, 2008) |
| "In this prospective randomized trial, we compared the efficacy and toxicity of cladribine (2-CdA) alone to 2-CdA combined with cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC) in untreated progressive chronic lymphocytic leukemia (CLL)." | 2.72 | Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C ( Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Jamroziak, K; Kasznicki, M; Kloczko, J; Konopka, L; Kowal, M; Kuliczkowski, K; Robak, T; Skotnicki, AB; Stella-Holowiecka, B; Sulek, K; Tomaszewska, A; Warzocha, K; Zawilska, K, 2006) |
| " From August 1998 to December 2000 2-CdA was administered at a dosage of 0." | 2.70 | Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. ( Boguradzki, P; Błoński, JZ; Calbecka, M; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, I; Kasznicki, M; Konopka, L; Kuliczkowski, K; Moskwa-Sroka, B; Nowak, W; Robak, T; Skotnicki, AB; Stella-Hołowiecka, B; Sułek, J; Wołowiec, D, 2001) |
| "Eight patients had follicular lymphoma, and 11 had CLL/SLL." | 2.69 | Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial. ( Emmanouilides, C; Kunkel, L; Rasti, S; Rosen, P; Territo, M, 1998) |
| " Because its toxicities are minimal and do not overlap with the toxicities of standard chemotherapy, it is an appealing agent to use in combination with chemotherapy." | 2.69 | Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. ( Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 2000) |
| "Pentostatin has also been shown to have clinical activity in CLL and appears to be less toxic than its fludarabine counterpart, which may offer some important advantages." | 2.45 | Pentostatin treatment combinations in chronic lymphocytic leukemia. ( Kay, NE; Lamanna, N, 2009) |
| "Cladribine is a newer purine analogue and is of particular interest because it is resistant to deamination by adenosine deaminase." | 2.42 | Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. ( Armitage, JO; Hoelzer, D; Rummel, MJ; Tobinai, K, 2004) |
| "There were 32 small lymphocytic lymphomas and 111 marginal zone lymphomas." | 1.42 | Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients. ( Argnani, L; Broccoli, A; Casadei, B; Gandolfi, L; Maglie, R; Pellegrini, C; Pileri, S; Stefoni, V; Zinzani, PL, 2015) |
| "Interestingly, in chronic lymphocytic leukemia (CLL) patients, we found that the patients with β2-microglobulin (β2-MG) < 3." | 1.42 | Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. ( Feng, X; Gu, Z; Li, F; Li, Z; Liu, W; Qi, J; Qiu, L; Xu, Y; Yi, S; Yu, Z; Zhan, F; Zou, D, 2015) |
| "Mitoxantrone treatment induced γH2AX foci and NU7441 increased their longevity (24 h)." | 1.37 | Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. ( Bedwell, C; Crawford, C; Durkacz, BW; Elliott, SL; Evans, P; Mainou-Fowler, T; Mulligan, E; Newton, P; Summerfield, G; Wallis, J; Willmore, E, 2011) |
| "We studied 40 patients with B-cell chronic lymphocytic leukemia (B-CLL) at diagnosis, before treatment and four weeks after therapy." | 1.33 | Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL. ( Bukin, M; Jabłońska, E; Kiersnowska-Rogowska, B; Parfieńczyk, A; Puzewska, W; Rogowski, F, 2005) |
| "Seventeen patients had small lymphocytic lymphoma (SLL), 29 had follicular lymphoma (FL), 10 of them with histologic transformation." | 1.31 | Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. ( Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Ladetto, M; Novero, D; Pileri, A; Rossi, G; Tarella, C; Zallio, F, 2000) |
| "B cell chronic lymphocytic leukemia (B-CLL) is an incurable clonal disease which shows initial responsiveness to a number of chemotherapeutic drugs." | 1.31 | Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis. ( Eigler, A; Emmerich, B; Endres, S; Loher, F; Meinhardt, G; Siegmund, B; Welsch, J, 2001) |
| " These results support that fludarabine in combination with cyclophosphamide and/or mitoxantrone can be highly effective in the treatment of B-CLL." | 1.30 | In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. ( Bellosillo, B; Colomer, D; Gil, J; Montserrat, E; Pons, G; Villamor, N, 1999) |
| " The median terminal half-life for mitoxantrone was similar to that of the mono- and dicarboxylic acid and was 75 h." | 1.29 | New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites. ( Hiddemann, W; Kamischke, A; Kaufmann, CC; Schleyer, E; Unterhalt, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (13.11) | 18.2507 |
| 2000's | 41 (67.21) | 29.6817 |
| 2010's | 12 (19.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Robak, T | 8 |
| Blonski, JZ | 3 |
| Gora-Tybor, J | 5 |
| Calbecka, M | 3 |
| Dwilewicz-Trojaczek, J | 4 |
| Boguradzki, P | 2 |
| Dmoszynska, A | 4 |
| Kowal, M | 2 |
| Kloczko, J | 2 |
| Piszcz, J | 1 |
| Stella-Holowiecka, B | 2 |
| Sulek, K | 2 |
| Kuliczkowski, K | 3 |
| Potoczek, S | 1 |
| Warzocha, K | 2 |
| Lech-Maranda, E | 3 |
| Skotnicki, AB | 3 |
| Piotrowska, M | 1 |
| Moskwa, A | 1 |
| Zawilska, K | 2 |
| Jamroziak, K | 2 |
| Abrisqueta, P | 2 |
| Villamor, N | 6 |
| Terol, MJ | 2 |
| González-Barca, E | 3 |
| González, M | 2 |
| Ferrà, C | 2 |
| Abella, E | 3 |
| Delgado, J | 2 |
| García-Marco, JA | 1 |
| González, Y | 2 |
| Carbonell, F | 2 |
| Ferrer, S | 2 |
| Monzó, E | 2 |
| Jarque, I | 2 |
| Muntañola, A | 3 |
| Constants, M | 1 |
| Escoda, L | 3 |
| Calvo, X | 1 |
| Bobillo, S | 1 |
| Montoro, JB | 1 |
| Montserrat, E | 6 |
| Bosch, F | 5 |
| Zinzani, PL | 1 |
| Pellegrini, C | 1 |
| Broccoli, A | 1 |
| Gandolfi, L | 1 |
| Stefoni, V | 1 |
| Casadei, B | 1 |
| Maglie, R | 1 |
| Argnani, L | 1 |
| Pileri, S | 1 |
| Li, Z | 1 |
| Li, F | 1 |
| Yi, S | 1 |
| Gu, Z | 1 |
| Yu, Z | 1 |
| Xu, Y | 1 |
| Feng, X | 1 |
| Liu, W | 1 |
| Zou, D | 1 |
| Qi, J | 1 |
| Zhan, F | 1 |
| Qiu, L | 1 |
| Cohen, JB | 1 |
| Bucur, S | 1 |
| Winton, EF | 1 |
| Sinha, R | 1 |
| Heffner, LT | 1 |
| King, N | 1 |
| Lonial, S | 1 |
| Langston, AA | 1 |
| Waller, EK | 1 |
| Hutchison-Rzepka, A | 1 |
| Colbert, A | 1 |
| Lechowicz, MJ | 1 |
| Flowers, CR | 1 |
| Munir, T | 1 |
| Howard, DR | 1 |
| McParland, L | 1 |
| Pocock, C | 2 |
| Rawstron, AC | 2 |
| Hockaday, A | 1 |
| Varghese, A | 1 |
| Hamblin, M | 1 |
| Bloor, A | 1 |
| Pettitt, A | 2 |
| Fegan, C | 2 |
| Blundell, J | 1 |
| Gribben, JG | 1 |
| Phillips, D | 1 |
| Hillmen, P | 2 |
| Nabhan, C | 1 |
| Lamanna, N | 1 |
| Kay, NE | 1 |
| Faderl, S | 1 |
| Wierda, W | 1 |
| O'Brien, S | 3 |
| Ferrajoli, A | 2 |
| Lerner, S | 2 |
| Keating, MJ | 2 |
| González Diaz, M | 1 |
| García Marco, JA | 1 |
| Estany, C | 1 |
| Salamero, O | 1 |
| Friedberg, JW | 1 |
| Zagoskina, TP | 1 |
| Tkachenko, SB | 1 |
| Golubeva, ME | 1 |
| Kudriavtseva, AV | 1 |
| Isaeva, NV | 1 |
| Malykh, OV | 1 |
| Weide, R | 5 |
| Mergenthaler, U | 1 |
| Friesenhahn, V | 1 |
| Kleboth, K | 1 |
| Heymanns, J | 4 |
| Thomalla, J | 1 |
| Köppler, H | 5 |
| Elliott, SL | 1 |
| Crawford, C | 1 |
| Mulligan, E | 1 |
| Summerfield, G | 1 |
| Newton, P | 1 |
| Wallis, J | 1 |
| Mainou-Fowler, T | 1 |
| Evans, P | 1 |
| Bedwell, C | 1 |
| Durkacz, BW | 1 |
| Willmore, E | 1 |
| Cohen, DR | 1 |
| Cocks, K | 1 |
| Sayala, HA | 1 |
| Kennedy, DB | 1 |
| Milligan, DW | 1 |
| Radford, J | 1 |
| Mercieca, J | 1 |
| Dearden, C | 1 |
| Ezekwisili, R | 1 |
| Smith, AF | 1 |
| Brown, J | 1 |
| Booth, GA | 1 |
| Varghese, AM | 1 |
| Cervigón, I | 1 |
| Palomo, A | 1 |
| Torres-Iglesias, LM | 1 |
| Solano, F | 1 |
| Zapata, AM | 1 |
| Fuss, H | 1 |
| Hurtz, HJ | 1 |
| Knigge, O | 1 |
| Losem, C | 1 |
| Reschke, D | 1 |
| Schmitz, S | 1 |
| Weiß, J | 1 |
| Hallek, M | 2 |
| Telek, B | 1 |
| Rejtó, L | 1 |
| Kiss, A | 1 |
| Batár, P | 1 |
| Reményi, G | 1 |
| Rák, K | 1 |
| Udvardy, M | 1 |
| Schmitt, B | 1 |
| Wendtner, CM | 1 |
| Bergmann, M | 1 |
| Busch, R | 1 |
| Franke, A | 1 |
| Pasold, R | 1 |
| Schlag, R | 1 |
| Hopfinger, G | 1 |
| Hiddemann, W | 5 |
| Emmerich, B | 2 |
| Bellosillo, B | 4 |
| López-Guillermo, A | 2 |
| Marcé, S | 1 |
| Campo, E | 1 |
| Colomer, D | 4 |
| Mauro, FR | 1 |
| Foa, R | 1 |
| Meloni, G | 1 |
| Gentile, M | 1 |
| Giammartini, E | 1 |
| Giannarelli, D | 1 |
| De Propris, MS | 1 |
| Rapanotti, MC | 1 |
| de Fabritiis, P | 1 |
| Mandelli, F | 1 |
| Boński, JZ | 1 |
| Kasznicki, M | 5 |
| Hellmann, A | 1 |
| Konopka, L | 3 |
| Wołowiec, D | 2 |
| Forstpointner, R | 2 |
| Hänel, A | 1 |
| Repp, R | 1 |
| Hermann, S | 1 |
| Metzner, B | 1 |
| Pott, C | 1 |
| Hartmann, F | 1 |
| Rothmann, F | 1 |
| Böck, HP | 1 |
| Wandt, H | 1 |
| Unterhalt, M | 3 |
| Ferrer, A | 2 |
| Giné, E | 2 |
| Cobo, F | 1 |
| Perales, M | 1 |
| Esteve, J | 1 |
| Altés, A | 2 |
| Besalduch, J | 1 |
| Ribera, JM | 1 |
| Adiga, GU | 1 |
| Abebe, L | 1 |
| Wiernik, PH | 1 |
| Shvidel, L | 1 |
| Shtalrid, M | 1 |
| Bairey, O | 1 |
| Rahimi-Levene, N | 1 |
| Lugassy, G | 1 |
| Shpilberg, O | 1 |
| Polliack, A | 1 |
| Berrebi, A | 1 |
| Scaramucci, L | 1 |
| Niscola, P | 1 |
| Buffolino, S | 1 |
| Bongarzoni, V | 1 |
| Cimino, G | 1 |
| Montanaro, M | 1 |
| Tsimberidou, AM | 1 |
| Giles, FJ | 1 |
| Wierda, WG | 1 |
| Beran, M | 1 |
| Andreeff, M | 1 |
| Kantarjian, HM | 1 |
| Armitage, JO | 1 |
| Tobinai, K | 1 |
| Hoelzer, D | 2 |
| Rummel, MJ | 2 |
| Pandorf, A | 2 |
| Hendry, L | 1 |
| Bowen, A | 1 |
| Matutes, E | 1 |
| Swansbury, J | 1 |
| Catovsky, D | 1 |
| Rogalińska, M | 1 |
| Błoński, JZ | 4 |
| Hanausek, M | 2 |
| Walaszek, Z | 2 |
| Kiliańska, ZM | 2 |
| Lin, TS | 1 |
| Grever, MR | 1 |
| Byrd, JC | 2 |
| Jabłońska, E | 1 |
| Kiersnowska-Rogowska, B | 1 |
| Rogowski, F | 1 |
| Parfieńczyk, A | 1 |
| Puzewska, W | 1 |
| Bukin, M | 1 |
| Tomaszewska, A | 1 |
| Ceglarek, B | 2 |
| Hanamura, A | 1 |
| Hayakawa, M | 1 |
| Naito, K | 1 |
| Nickenig, C | 1 |
| Dreyling, M | 1 |
| Hoster, E | 1 |
| Ludwig, WD | 1 |
| Dörken, B | 1 |
| Freund, M | 2 |
| Huber, C | 1 |
| Ganser, A | 1 |
| Trümper, L | 1 |
| Kobylinska, A | 1 |
| Bednarek, J | 1 |
| Szmigielska-Kapłon, A | 1 |
| Jesionek-Kupnicka, D | 1 |
| Kordek, R | 1 |
| Quiney, C | 1 |
| Billard, C | 1 |
| Faussat, AM | 1 |
| Salanoubat, C | 1 |
| Kolb, JP | 1 |
| Zhao, X | 1 |
| Wu, J | 1 |
| Muthusamy, N | 1 |
| Lee, RJ | 1 |
| Weingrill, E | 1 |
| Wölfler, A | 1 |
| Strunk, D | 1 |
| Linkesch, W | 1 |
| Sill, H | 1 |
| Liebmann, PM | 1 |
| Briones, J | 1 |
| Gardella, S | 1 |
| Pérez-Ceballos, E | 1 |
| Asensi, A | 1 |
| Sayas, MJ | 1 |
| Font, L | 1 |
| Bertazzoni, P | 1 |
| Rozman, M | 1 |
| Aymerich, M | 1 |
| Lü, SQ | 1 |
| Yang, JM | 1 |
| Song, XM | 1 |
| Chen, L | 1 |
| Zhang, WP | 1 |
| Ni, X | 1 |
| Xu, XQ | 1 |
| Wang, JM | 1 |
| Schleyer, E | 1 |
| Kamischke, A | 1 |
| Kaufmann, CC | 1 |
| McConkey, DJ | 1 |
| Chandra, J | 1 |
| Wright, S | 1 |
| Plunkett, W | 1 |
| McDonnell, TJ | 1 |
| Reed, JC | 1 |
| Keating, M | 1 |
| Pons, G | 2 |
| Gil, J | 2 |
| Emmanouilides, C | 1 |
| Rosen, P | 1 |
| Rasti, S | 1 |
| Territo, M | 1 |
| Kunkel, L | 1 |
| Tarella, C | 1 |
| Caracciolo, D | 1 |
| Corradini, P | 1 |
| Zallio, F | 1 |
| Ladetto, M | 1 |
| Cuttica, A | 1 |
| Rossi, G | 1 |
| Novero, D | 1 |
| Gavarotti, P | 1 |
| Pileri, A | 1 |
| McLaughlin, P | 1 |
| Hagemeister, FB | 1 |
| Rodriguez, MA | 1 |
| Sarris, AH | 1 |
| Pate, O | 1 |
| Younes, A | 1 |
| Lee, MS | 1 |
| Dang, NH | 1 |
| Romaguera, JE | 1 |
| Preti, AH | 1 |
| McAda, N | 1 |
| Cabanillas, F | 1 |
| Góra-Tybor, I | 1 |
| Sułek, J | 1 |
| Stella-Hołowiecka, B | 1 |
| Nowak, W | 1 |
| Moskwa-Sroka, B | 1 |
| Siegmund, B | 1 |
| Welsch, J | 1 |
| Loher, F | 1 |
| Meinhardt, G | 1 |
| Endres, S | 1 |
| Eigler, A | 1 |
| Seymour, JF | 1 |
| Grigg, AP | 1 |
| Szer, J | 1 |
| Fox, RM | 1 |
| Chow, KU | 1 |
| Sommerlad, WD | 1 |
| Boehrer, S | 1 |
| Schneider, B | 1 |
| Seipelt, G | 1 |
| Mitrou, PS | 1 |
| Weidmann, E | 1 |
| Gores, A | 1 |
| Hansen, MM | 1 |
| Hansen, SW | 1 |
| Pedersen-Bjergaard, J | 1 |
| Nissen, NI | 1 |
| Wunsch-Zeddies, S | 1 |
| Schäfers, M | 1 |
| Wysk, J | 1 |
| Seidel, I | 1 |
| Hanauske, AR | 1 |
| Link, H | 1 |
| Schmoll, HJ | 1 |
| Poliwoda, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab in Patients With Low Grade Non-Hodgkins Lymphoma: An Analysis of Efficacy and Tolerability[NCT00208975] | Phase 2 | 15 participants (Actual) | Interventional | 2002-07-31 | Terminated (stopped due to slow accrual) | ||
| Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798] | Phase 3 | 22 participants (Actual) | Interventional | 2019-12-09 | Active, not recruiting | ||
| A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) With or Without Rituximab in Previously Treated Chronic Lymphocytic Leukemia[NCT00337246] | Phase 2 | 56 participants (Anticipated) | Interventional | 2005-07-31 | Completed | ||
| Treatment of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL) WITH Bendamustine / Mitoxantrone (BM)[NCT00274963] | Phase 2 | 60 participants (Anticipated) | Interventional | 2004-10-31 | Completed | ||
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883] | Phase 1 | 9 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588] | Phase 1 | 4 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase II Study of Rituximab in Combination With Fludarabine and Cyclophosphamide for the Treatment of Relapsed Follicular Lymphoma[NCT00393107] | Phase 2 | 54 participants | Interventional | 2000-03-31 | Completed | ||
| Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy[NCT01626352] | Phase 2 | 22 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Response (CR): Disappearance of all clinical evidence of active tumor for a minimum of eight weeks and absence of any symptoms related to the tumor.~Partial Response (PR):50% decrease in the sum of the product diameters of all lesions that persist for at least four weeks. No lesion can increase in size and no new lesion can appear during this period.~Stable disease (SD):A tumor that is neither growing nor shrinking.No new tumors have developed" (NCT00208975)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | |
| Chronic Lymphocytic Leukemia | 4 | 2 | 1 |
| Non Hodgkin Lymphoma | 5 | 2 | 0 |
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
Defined as the time from date of first documented confirmed response to date of disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. Patients who begin further anticancer therapy prior to disease progression will be censored at the date of last tumor assessment prior to the start date of the anticancer therapy. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle and every 3 months thereafter until disease progression or relapse from complete response for up to 38 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 5.6 |
Disease response assessments will be performed using the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires a disappearance of all evidence of disease. (NCT01626352)
Timeframe: 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 7 |
A treatment-related adverse event was any untoward medical occurrence in a participant which was considered to have a relationship with the study drug (suspected to be possibly or probably related to the study drug per the Investigator's assessment). Adverse events were evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and up to 30 days after last dose, projected 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 16 |
Overall response is the number of patients with observed complete or partial response (CR or PR) as assessed using the International Working Group (IMW) revised response criteria for malignant lymphoma (Cheson 2007). Complete response requires disappearance of all evidence of disease. Partial response requires regression of measurable disease and no new sites. (NCT01626352)
Timeframe: after cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter, projected 18 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bendamustine/Ofatumumab | 19 |
Defined as the time from Day 1 of study drug administration to date of death from any cause. (NCT01626352)
Timeframe: every 3 cycles during treatment and every 3 months thereafter until progression or death from any cause, projected 18 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 12.0 |
Defined as the time from first treatment until objective tumor progression, relapse from complete response, or death from any cause. Tumor response is defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. Patients who are alive and free from disease progression will be censored at the date of last tumor assessment. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 8.6 |
Defined as the time from date of first treatment to the date of first documented disease progression or relapse from complete response as defined by the International Working Group (IMW)-revised response criteria for malignant lymphoma (Cheson 2007). This criteria categorizes the response of a patient's tumor to treatment as Complete Response (CR): the disappearance of all disease evidence; Partial Response (PR): regression of measurable disease and no new sites; Stable Disease (SD): less than a PR but not progressive disease (PD); Relapsed Disease or PD: Any new lesion or increase by ≥ 50% of previously involved sites from nadir. (NCT01626352)
Timeframe: After cycles 3 and 6 of each 21-day cycle, and every 3 months thereafter until progression or relapse from complete response for up to 40 months
| Intervention | months (Median) |
|---|---|
| Bendamustine/Ofatumumab | 10.5 |
7 reviews available for mitoxantrone and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Pentostatin treatment combinations in chronic lymphocytic leukemia.
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodie | 2009 |
[Specific palatal infiltration in B-cell chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 2011 |
[Experience with fludarabine treatment and review of the literature].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 2002 |
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodie | 2002 |
Partially successful treatment of a patient with chronic lymphocytic leukemia and Hodgkin's disease: case report and literature review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bowen's Disease; Co | 2003 |
Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, | 2004 |
Clinical challenges in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Granulocyte Colony-St | 1998 |
26 trials available for mitoxantrone and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cyclophosphamide; Humans | 2014 |
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area U | 2013 |
Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2015 |
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2017 |
Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2010 |
Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2009 |
[Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; | 2010 |
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2012 |
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progressio | 2002 |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antine | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Diseas | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Diseas | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Diseas | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Diseas | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Diseas | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Diseas | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Diseas | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Diseas | 2002 |
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cyclophosphamide; Diseas | 2002 |
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up | 2004 |
Bendamustine plus mitoxantrone--a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, C | 2004 |
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclopho | 2006 |
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophospham | 2007 |
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Hum | 2008 |
Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; H | 1998 |
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2000 |
Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cladribine; Cyclophospha | 2001 |
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cohort Stud | 2001 |
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobiliz | 2001 |
Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Anti | 2002 |
Mitoxantrone in the treatment of chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle | 1992 |
28 other studies available for mitoxantrone and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2015 |
Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2015 |
Frontline therapy for chronic lymphocytic leukemia: the dilemma continues.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cost-Benefit Analysis; Cyc | 2008 |
Bendamustine in chronic lymphocytic leukemia: the future is combination therapy.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine | 2009 |
Bendamustine/mitoxantrone/rituximab: a short remission induction chemoimmunotherapy for elderly patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2009 |
Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Chromones; Culture Media, Conditioned; D | 2011 |
Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer | 2002 |
Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclopho | 2002 |
Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2003 |
Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplasti | 2004 |
2-Chlorodeoxyadenosine alone and in combination with cyclophosphamide and mitoxantrone induce apoptosis in B chronic lymphocytic leukemia cells in vivo.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Cladribine; Cyclophosphamide; Female; Humans; Leukemi | 2004 |
Changing the way we think about chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Case-Contr | 2005 |
[Mantle cell lymphoma mimicking chronic lymphocytic leukemia].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Blotting, Western; Caspa | 2006 |
Influence of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone on bone marrow angiogenesis in chronic lymphocytic leukemia.
Topics: Adult; Aged; Bone Marrow Cells; Cladribine; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, | 2007 |
Hyperforin inhibits P-gp and BCRP activities in chronic lymphocytic leukaemia cells and myeloid cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transp | 2007 |
Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemistry, Pharmaceutical; Drug Stability | 2008 |
Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2007 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexa | 2007 |
New aspects on the pharmacokinetics of mitoxantrone and its two major metabolites.
Topics: Acute Disease; Adult; Carboxylic Acids; Half-Life; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B | 1994 |
Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; DNA, Neoplasm | 1996 |
Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Dose-Response Relationship | 1998 |
In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Apop | 1999 |
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cycloph | 2000 |
Phosphodiesterase type 4 inhibitor suppresses expression of anti-apoptotic members of the Bcl-2 family in B-CLL cells and induces caspase-dependent apoptosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Aged; Antineoplastic Agents; Apoptosis; Caspases; Cyclic Nucleo | 2001 |
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Der | 2002 |
Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, | 1992 |